[Infographics] Slow down lung function decline in CTD-ILD with nintedanib

Nintedanib is the only antifibrotic approved in Hong Kong for progressive pulmonary fibrosis and systemic sclerosis–associated interstitial lung disease (ILD). Read further on how nintedanib slows lung function decline in connective tissue disease–associated ILD (CTD-ILD), as well as ERS/EULAR 2025 guideline recommendations on screening, diagnosis, monitoring, and treatment of CTD-ILD.